Impact of TME on the Efficacy of PD-L1 Blockade in NSCLC

Abstract

Non-small cell lung cancer (NSCLC) is one of the most common cancer types worldwide, and treatment options are complex and individualized. Immune checkpoint inhibitors, particularly therapeutic strategies targeting the PD-1/PD-L1 pathway, have resulted in significant prognostic improvements for some patients. The tumor microenvironment (TME) plays an important role in affecting the therapeutic effect of NSCLC, but its mechanism still needs to be understood in depth. In recent years, research has begun to focus on how to improve the efficacy of PD-L1 blockade therapy by regulating the TME. Some strategies aim to increase the infiltration of cytotoxic T cells in the TME or reduce the impact of immunosuppressive cells to enhance the efficacy of immune checkpoint inhibitors. Changing the metabolic properties of the TME may become one of the new strategies to enhance PD-L1 blockade therapy. Studies have shown that by effectively changing the metabolic properties of the TME, the efficacy of PD-L1 blockade therapy may be enhanced. Future studies should focus on uncovering the interaction of various components of the TME and how they jointly influence NSCLC’s response to therapy. An in-depth understanding of the impact of TME on NSCLC treatment will help optimize immunotherapy strategies and improve patients’ survival rate and quality of life. Future research can focus on studying how the various components of the TME interact and developing new strategies to regulate the TME, thereby expanding new avenues for NSCLC treatment.